Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds

Background. There has been much recent interest in accumulation of advanced glycation end-products (AGE) in uraemic patients. Analysis of AGE has been difficult, because commonly used methodologies, i.e. immunodetection assays or fluorescence measurements, reflect group reactivity and are not specif...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 1999-08, Vol.14 (8), p.1968-1975
Main Authors: Henle, Thomas, Deppisch, Reinhold, Beck, Werner, Hergesell, Olaf, Hänsch, Gertrud M., Ritz, Eberhard
Format: Article
Language:English
Subjects:
Adult
advanced glycation end-products
Aged
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Arginine - analogs & derivatives
Arginine - blood
Biological and medical sciences
Chromatography, High Pressure Liquid
diabetes
Emergency and intensive care: renal failure. Dialysis management
Female
Fluorescence
Glycation End Products, Advanced - blood
Glycation End Products, Advanced - chemistry
Hemofiltration
high-flux haemodialysis
HPLC
Humans
Intensive care medicine
Lysine - analogs & derivatives
Lysine - blood
Maillard products
Male
Medical sciences
Middle Aged
Molecular Weight
Norleucine - analogs & derivatives
Norleucine - blood
pentosidine
Pyrroles - blood
Renal Dialysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. There has been much recent interest in accumulation of advanced glycation end-products (AGE) in uraemic patients. Analysis of AGE has been difficult, because commonly used methodologies, i.e. immunodetection assays or fluorescence measurements, reflect group reactivity and are not specific for chemically defined substances. Some investigators measured individual AGE compounds, e.g. pentosidine, carboxymethyllysine, pyrraline or imidazolone, but a systematic assessment of known compounds using specific HPLC methods in diabetic and non-diabetic end-stage renal disease (ESRD) patients during treatment has not been performed. Methods. For the present study, the concentrations of early and late products of the Maillard reaction in plasma and ultrafiltrate were monitored during high-flux dialysis sessions in diabetic and non-diabetic patients. AGE were analysed by fluorescence spectroscopy and size exclusion chromatography with fluorescence detection. Specific HPLC methods were used to quantify the Amadori product fructoselysine and the AGE compounds pentosidine and pyrraline in acid or enzymatic hydrolysates. Results. Using size exclusion chromatography, we confirmed a similar fluorescent peak distribution for diabetic and non-diabetic ESRD patients. Main fractions were found at ∼70, ∼14 and
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/14.8.1968